TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02681198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Description: All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
Study: NCT02854046

Intervention type: OTHER
Intervention: Calcific Uremic Arteriolopathy
Study: NCT03082690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DuoGel
Description: 1% IQP-0528 in gel formulation
Study: NCT01259141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: 0.4 Qd for 7days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalosporins and azithromycin
Description: cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
Study: NCT02507765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization
Description: Undergo TACE
Study: NCT02153632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine HCl ER
Description: Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine HCl ER
Description: Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects are given an identical placebo tablet
Study: NCT02352480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurix
Description: Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
Study: NCT04960449

Intervention type: PROCEDURE
Intervention: shoulder arthroscopy
Description: Patients underwent ubacromial bursectomy and acromioplasty , cuff debridement and cuff repair, side to side suture of rotator cuff combined with suture anchor.
Study: NCT03151629

Intervention type: OTHER
Intervention: Standard of Care
Description: Drugs routinely administered for metastatic prostate cancer per local standard.

Intervention type: OTHER
Intervention: Standard of Care
Description: Drugs routinely administered for metastatic prostate cancer per local standard.
Study: NCT03226002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq NT
Description: channeled video laryngoscope for nasotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq NT
Description: channeled video laryngoscope for nasotracheal intubation
Study: NCT00604565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: soluble ferric pyrophosphate (SFP)
Description: Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
Study: NCT04254393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Adolescent Skills for Emotions (EASE) Program
Description: EASE has been developed to manage and reduce symptoms of depression, anxiety and distress in adolescents. EASE is designed to be delivered by non-specialists in low resource settings such as a trained school-health counsellor. The intervention comprises of 7 young adolescent group sessions, each lasting 90 minutes and involves the empirically supported components of psycho education, problem solving, stress management (slow breathing), behavioural activation, and relapse prevention and 3 caregiver group sessions, each lasting 120 minutes and involve psycho education, active listening, quality time, praise, caregiver self-care and relapse prevention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment As Usual (TAU)
Description: Evidence based health practices are not available in schools to manage the mental health problems of children. No structured programs are being implemented in school settings for at-risk children. During the study, participants in TAU showing severe psychiatric symptoms that require immediate specialist treatment and follow-up, will be referred to the Institute of psychiatry (IoP)-the tertiary mental health care facility of the region.
Study: NCT02260934

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab 1000mg intravenously (IV) at week 0 and week 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: * Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Week 0 and Week 2:~Solumedrol (100 mg) IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 1000mg intravenously (IV) at week 0 and week 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: * Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Week 0 and Week 2: Solumedrol (100 mg) IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
Study: NCT02304939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: changeover

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: changeover

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: changeover

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: use of automatic infusion pump

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: datas collection

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: datas collection

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: datas collection
Study: NCT00928902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose IL-2
Description: low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose IL-2
Description: low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: melanoma vaccine
Description: six melanoma vaccines given over a 6-week period

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: melanoma vaccine
Description: six melanoma vaccines given over a 6-week period
Study: NCT00152503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seletracetam (UCB44212)
Description: * Pharmaceutical form: oral capsules~* Concentration: 2, 10 and 50 mg~* Route of administration: oral administration
Study: NCT01862289

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic of chronic hyperventilation syndrome
Description: Nijmegen questionnaire, Hyperventilation challenge and blood gases
Study: NCT00768417

Intervention type: BEHAVIORAL
Intervention: 10 chews
Description: Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.

Intervention type: BEHAVIORAL
Intervention: 25 Chews
Description: Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.

Intervention type: BEHAVIORAL
Intervention: 40 Chews
Description: Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
Study: NCT01300234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) tablets
Description: white, almond-shaped, film-coated tablets containing 300mg of TDF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adefovir dipivoxil (ADV) tablets
Description: white to off-white, round, biconvex tablets containing 10mg of ADV
Study: NCT01849601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous transluminal angioplasty balloon catheter
Study: NCT01271556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: 50 mcg MDI (inhalatory), once on days A and C at t=0,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: 50 mcg MDI (inhalatory), once on days A and C at t=0,

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline infusion (0.9 per cent sodium chloride)
Description: rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: saline infusion (0.9 per cent sodium chloride)
Description: rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, inhalatory (MDI) once

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, inhalatory (MDI) once
Study: NCT03201588

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Formulaid
Description: Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
Study: NCT01799096

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aspartame
Description: Intensely sweetened soft drink (no energy content)
Study: NCT04100031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: phacoemulsification
Description: underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification
Description: underwent standard phacoemulsification through a 2.8-mm clear corneal temporal incision and intraocular lens
Study: NCT04566471

Intervention type: OTHER
Intervention: prevalence/incidence
Description: It is an observational study for prevalence/incidence, no intervention provided.
Study: NCT02168114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercising
Description: This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical and Magnetic Resonance Imaging and Spectroscopy
Description: This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optical and Magnetic Resonance Imaging and Spectroscopy
Description: This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
Study: NCT04957797

Intervention type: PROCEDURE
Group type: OTHER
Intervention: round tunnel
Description: reamed with round tunnel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: flat tunnel
Description: reamed with flat tunnel
Study: NCT05456737

Intervention type: OTHER
Intervention: assessment
Description: Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.

Intervention type: OTHER
Intervention: assessment
Description: Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
Study: NCT03864822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition Transcranial Direct Current Stimulation
Description: Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: High-Definition Transcranial Direct Current Stimulation
Description: Device uses an array of electrodes over the scalp, in contact via gel, to provide a weak electrical current.
Study: NCT05456737

Intervention type: OTHER
Intervention: assessment
Description: Application of various assessment methods to determine the foot characteristics, foot posture, functional activity, balance levels and quality of life of the determined groups.
Study: NCT00841334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTION
Description: Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
Study: NCT01845935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)
Description: Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
Study: NCT04130607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conceptual teaching
Description: The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conceptual teaching
Description: The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conceptual teaching
Description: The present study is designed to contrast two instructional methods - explicit instruction in likelihood ratios and pretest/posttest probabilities versus implicit instruction based on presentation of multiple cases. These will be compared to a no intervention control group.
Study: NCT04388761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose derived mesenchymal stem cells
Description: Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose derived mesenchymal stem cells
Description: Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose derived mesenchymal stem cells
Description: Injection of Allogeneic adipose derived mesenchymal stem cells into the Kidney allograft
Study: NCT00195936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Single oral dose of Cinacalcet for children with Hypophosphatemic Rickets
Study: NCT04265014

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Goal-directed fluid treatment
Description: Goal-directed fluid treatment for major abdominal surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Fluid Therapy
Description: Liberal Fluid Therapy for major abdominal surgery
Study: NCT02608658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)
Description: Visit 1, screening (Day 0): At this visit, the investigators of the study will:~* Obtain demographic information, as will past medical history and medications.~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test~From Day 0 to 8 weeks: subjects will take the medical food twice daily~Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination~* Collect and record returned investigational product~* Dispense investigational product and instruct again regarding use~* Record any adverse events~Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:~* Perform a physical examination.~* Collect samples for labs~* Administer the Chronic Liver Disease Questionnaire (CLDQ)~* Perform a lactulose breath test
Study: NCT04299165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaia COPD Application
Description: The study intervention consists of training sessions conducted daily by the patient via the COPD-App.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The control group will also be an active control as participants receive a leaflet to convey an active lifestyle and a list of exercises to do at home.
Study: NCT03564717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmented three dimensionally printed transfer tray
Description: Segmented indirect bonding transfer tray
Study: NCT03095079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human endostatin
Description: Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m\^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle~Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14
Study: NCT00471692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivicaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivicaine
Study: NCT03332381

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention training technique
Description: Attention training involves modifying metacognitive control and enhancing attention flexibility so that people can refrain from responding to intrusions with extended processing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindful self-compassion
Description: Self-compassion involves not avoiding painful or distressing feelings. Instead these experiences are held in awareness with kindness, understanding, and a sense of shared humanity.
Study: NCT03814707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of 0.2% hyaluronic acid gel
Description: Topical application of 0.2% hyaluronic acid gel will be placed immediately in palatal donor site after free gingival graft harvesting

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin
Description: Placement of Platelet rich fibrin in the palatal donor sie after free gingival graft harvesting and suturing by criss cross sutured then covered by periodontal pack.
Study: NCT02372526

Intervention type: OTHER
Intervention: Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes

Intervention type: OTHER
Intervention: Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes

Intervention type: OTHER
Intervention: Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes

Intervention type: OTHER
Intervention: Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes

Intervention type: OTHER
Intervention: Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes

Intervention type: OTHER
Intervention: Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes

Intervention type: OTHER
Intervention: Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes

Intervention type: OTHER
Intervention: Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes
Study: NCT03983629

Intervention type: OTHER
Intervention: Collection of data and genetic analysis
Description: Data collected are: History of disease, medical history, family medical history, biological results, Imaging results, disease progression Genetic analysis will be performed with whole genome and whole exome sequencing
Study: NCT02709213

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic
Description: Determination of pathogens and faecal calprotectin in the stools
Study: NCT02128542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)